A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas
Phase of Trial: Phase I/II
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs Temozolomide (Primary) ; TRC 102 (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Lymphoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 19 Jul 2019 Planned End Date changed from 24 Dec 2020 to 1 Feb 2021.
- 18 Jul 2019 Planned End Date changed from 1 Feb 2020 to 24 Dec 2020.
- 18 Jul 2019 Planned primary completion date changed from 24 Dec 2019 to 24 Dec 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History